Last year’s flu season showed how quickly demand for healthcare can rise.
Emergency department attendances for acute respiratory infections increased from 9000 per week at the beginning of October 2025 to more than 17,000 per week at the peak in early December.
When demand rises this quickly, pharmaceutical manufacturers face a difficult task. They need to make more medicines, often in a relatively short period, while making sure that every tablet remains consistent in dose, robust and safe.
Manufacturers must know that the powders they are working with will behave in a predictable way as production increases.
With this in mind, Natalia Dadivanyan (pictured), Market Development Manager, Pharma Small Molecule at Malvern Panalytical, explains how manufacturers can maintain continuous production while ensuring consistent tablet quality.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
